Is there a progress in treatment of dyslipidemia in diabetes? What are the results of ACCORD study?

Abstract

In this article ACCORD Study results, concerning clinical efficacy in preventing cardiovascular disease and safety of combined statin and fibrate treatment in patients with type 2 diabetes in comparison to statin monotherapy are presented. Study included 5518 patients with type 2 diabetes, treated with simvastatin and fenofibrate in comparison to simvastatin and placebo. After 4.7 years of treatment no significant differences in primary end points (cardiac death, myocardial infarction and stroke) were observed between compared groups. However, favourable trend of combined therapy in comparison to statin monotherapy in the subgroup of patients with low HDL-cholesterol and high triglycerides — lipid profile typical for atherogenic dyslipidemia — 31% decrease of cardiovascular end-points was observed. The results of ACCORD Lipid Study suggest combined therapy according to patients’ lipid profile. (Diabet. Prakt. 2011; 12, 1: 1–5)